⚠ Tool for educational and informational purposes only — not investment advice or a recommendation to buy or sell. Investing carries risk of capital loss. Read the full disclaimer.

BTAI — BioXcel Therapeutics, Inc.

Last scan (Sept. 15, 2026): price $0.89, RSI 39.47, relative volume 0.42x, MACD ⚪ No, score 15.70.

It's trading below its 200-day average (weak underlying trend), with an RSI of 39.47. Neither the MACD nor a range breakout gives a technical entry signal right now. Relative volume of 0.42x is below normal — little interest today.

back to scanner

Price chart

Not enough data for this period.

What analysts say

BTAI

BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of…

No data
1 analysts
  • Buy 1 (100.0%)
  • Hold 0 (0.0%)
  • Sell 0 (0.0%)

Healthy Moderate Attention No data

Market cap $2.31M

Total market value of the company (price × shares outstanding).

P/E (trailing) N/A

P/E (trailing): compares the stock's price with its earnings per share over the last 12 months — how many times that earning is being paid for.

Not enough data to calculate it (no recent earnings or data unavailable).

P/E (forward) -0.03

P/E (forward): same as P/E, but using analysts' estimated earnings per share for the next year.

Same as P/E, using estimated future earnings.

PEG N/A

PEG: the P/E divided by the expected earnings growth rate — relates how expensive the stock is to how fast it's expected to grow.

Not enough data (requires future growth estimates).

Debt/Equity N/A

Debt/Equity: how much debt the company carries per dollar of shareholder equity — measures how leveraged the balance sheet is.

Not enough data.

Net margin 0.0%

Net margin: what percentage of each dollar of revenue ends up as net profit, after all costs.

Low margin: the business has little cushion if costs rise.

Dividend N/A

Dividend: what percentage of the stock's price is paid out in cash to shareholders each year.

Doesn't pay dividends: reinvests earnings into growth instead of distributing them.

Beta (risk) 0.19

Beta: how volatile the stock is compared to the overall market (S&P 500 = 1.0).

Less volatile than the overall market (S&P 500 = 1.0).

General reference ranges, do not vary by sector. Third-party data; may be incomplete. Not investment advice.

💰 Financial Statements (last 3 quarters)

💰 Financial Statements (last 3 quarters)

Advertisement

What this chart shows

Third-party market data, for informational purposes. Not investment advice — read the disclaimer.